3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2015 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborators:
Janssen Scientific Affairs, LLC
OHSU Knight Cancer Institute
Rutgers Cancer Institute of New Jersey
NorthShore University HealthSystem
Duke University
Feinberg School of Medicine, Northwestern University
Sidney Kimmel Comprehensive Cancer Center
University of North Carolina
Wayne State University
Perlmutter New York University Cancer Center
Weill Medical College of Cornell University
Ferring Pharmaceuticals
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01751451
First received: December 14, 2012
Last updated: August 6, 2015
Last verified: August 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2016
  Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)